Inclusion Criteria

Patients must fulfill the following criteria:

• Diagnosis of AIDS or AIDS-related complex, according to CDC criteria, in previously documented HIV seropositive individuals.
• Failure to tolerate or respond to zidovudine (AZT) therapy for HIV infection or a decision to decline such therapy.
• Willingness to abstain from all other experimental therapy for HIV infection during study period.
• Life expectancy of at least 3 months.
• Patients must be able to sign a written informed consent form.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

• Serious active opportunistic infection or malignancies not specifically allowed.

Concurrent Medication:

Excluded:

• Oral or intravenous acyclovir for herpes.
• Zidovudine (AZT).
• Interferon.
• Corticosteroids.
• Nonsteroidal anti-inflammatory agents (NSAIDS).
• Intravenous acyclovir.
• Other known immunomodulatory agents.
• Other experimental therapy.

Patients with the following are excluded:

• Serious active opportunistic infection or malignancies not specifically allowed.

Prior Medication:

Excluded within 4 weeks of study entry:

• Zidovudine (AZT).
• Chemotherapy.
• Immunomodulatory agents.
• Other experimental therapy.